Skip to content

Clinical study of Arjuna, Manjishtha and Vasa (AMV) Cream in the treatment of Vyanga(Black discoloration of skin)

Pharmaceutical Development, Standardization and Clinical Evaluation of the efficacy of Arjuna, Manjishtha and Vasa (AMV) Lepa and Cream in Vyang (Melasma) - NIl

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/077043
Enrollment
44
Registered
2024-11-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

None listed

Sponsors

Ayurvedic and Unani Tibbia College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients belonging to the age group of 25 to 55 years 2. Patients with the classical signs and symptoms of disease Vyanga (Melasma) i.e Shyava (Varna), Tanu (alpa), Niruja mandalas 3.Patients having the chronicity of disease for less than 5 years 4.Patients not using any topical treatment for melasma for 2 weeks prior to enrollment in the study 5.Patients willing to participate in study trial and give written informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant women and lactating mothers. 2. Vyanga (Melasma) caused since birth like Nevus of Ota etc. 3. Patients having Vyanga (Melasma) as a symptom of major systemic diseases like S.L.E, Addison’s disease etc., or as a result of adverse effect of any drug or caused by tumor like malignant melanoma. 4. Patients taking oral contraceptive pills & injected depot contraceptive preparations.

Design outcomes

Primary

MeasureTime frame
1. Prepared and standardized AMV Cream. 2. Improvement in Clinical signs and symptoms of Vyanga (Melasma) 4. Improvement in Melasma Area and Severity Index Score (MASI Score) 4. Improvement in Physician global assessment scale (PAGI)Timepoint: 2 months

Secondary

MeasureTime frame
Improvement in the Melasma Quality of Life index (MELAS Qol)Timepoint: 2 months

Countries

India

Contacts

Public ContactDr Shalini Varshney

Ayurvedic and Unani Tibbia College and Hospital

shalinidr.v7@gmail.com9354925050

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026